Summary Companies SELECT trial tested medical benefits of Wegovy Results much better than expected Data could help expand Wegovy’s use Novo shares hit record highs COPENHAGEN/LONDON, Aug 8 (Reuters) – Novo Nordisk (NOVOb.CO) said on Tuesday a large late-stage study showed its obesity drug Wegovy had a clear medical benefit, in addition to weight loss, […]
Novo Nordisk’s U.S.-listed stock NVO, +3.04% NOVO.B, +10.35% rose 10% premarket Tuesday, after the company said its obesity treatment semaglutide, marketed as Wegovy, met its main goal in a trial evaluating its ability to reduce cardiovascular events and not just help with weight loss. The Danish company said a 2.4 mg dose of semaglutide reduced […]
In 2019, nearly 12 percent of Black individuals experienced pre-term births compared with 7 percent of White individuals, according to a new demography paper. Pre-pregnancy cardiovascular health (obesity, diabetes, hypertension) was the quantifiable difference but the authors also included vague factors like ‘prenatal care’ and ‘education’ – which are all self-reported, and how higher education […]
UNIVERSITY PARK, Pa. — Whether it’s work or play that prevents us from getting enough shut-eye during the week, assuming we can make up for it by sleeping in over the weekend is a mistake. New research led by Penn State reveals that cardiovascular health measures, including heart rate and blood pressure, worsen over the […]
Abstract This population-based cohort study aimed to describe changes in incidence of cardiovascular disease (CVD) hospital diagnoses during the COVID-19 pandemic in The Netherlands compared with the pre-pandemic period. We used Dutch nationwide statistics about hospitalizations to estimate incidence rate ratios (IRR) of hospital diagnoses of CVD during the first and second COVID-19 waves in […]
The director of the only pediatric heart transplant program in Louisiana, a married gay man, says he is relocating to New York for a better LGBTQ+ environment. (Advocate) Once-weekly semaglutide 2.4 mg (Wegovy) reduced major adverse cardiovascular events by 20% in the SELECT trial of patients with a body mass index (BMI) ≥27 and established […]
Study population This cohort study was a secondary analysis of the data from the CHARLS, an ongoing nationally representative cohort study among Chinese adults aged ≥ 45 years from 450 villages or resident communities within 28 provinces across China [20]. The study has conducted four main surveys, with the first wave being launched in 2011, and follow-up […]
For people with overweight or obesity, the weight loss drug Wegovy (semaglutide) can reduce the risk of developing or dying from events like heart attacks and strokes, according to preliminary results from a new study that offers the first major evidence that the medicine has cardiovascular benefits. For the study, researchers randomly assigned 17,604 adults […]
Bagsværd, Denmark, 8 August 2023 – Novo Nordisk today announced the headline results from the SELECT cardiovascular outcomes trial. The double-blinded trial compared subcutaneous once-weekly semaglutide 2.4 mg with placebo as an adjunct to standard of care for prevention of major adverse cardiovascular events (MACEs) over a period of up to five years. The trial […]
A particular protein normally used to rule out a heart attack could indicate a higher risk of death in a patient’s next couple of years – for any reason. Troponin is a heart protein, and high levels of it are often seen in hospital patients who don’t have specific signs of a heart attack. But […]